CytomX Therapeutics, Inc. (CTMX) has 20 bekannte Insider- und institutionelle Anteilseigner verzeichnet. Der größte Anteilseigner ist THIRD ROCK VENTURES LP mit 3,320,348 Aktien. Weitere bedeutende Anteilseigner sind SHANNON TIMOTHY M und Canaan IX L.P..
In den letzten 12 Monaten haben Insider 29 Transaktionen in CTMX Aktien getätigt — 17 Käufe (im Wert von $10.67M) und 8 Verkäufe (im Wert von $1.9M). Insider-Käufe haben die Verkäufe übertroffen, was auf Vertrauen in die Unternehmensaussichten hindeuten kann.
CTMX Insider-Beteiligungen
Größter Aktionär
THIRD ROCK VENTURES LP
3,320,348 Aktien
Käufe (12 Monate)
17
$10.67M Wert
Verkäufe (12 Monate)
8
$1.9M Wert
12-Monats-Transaktionsaktivität
Top-Insider-Aktionäre
| # |
Name |
Funktion |
Gehaltene Aktien |
Zuletzt gemeldet |
Relative Größe |
| 1 |
Third Rock Ventures Lp |
10 Percent Owner |
3,320,348 |
2017-10-19 |
|
| 2 |
Shannon Timothy M |
Director |
3,244,381 |
2016-12-01 |
|
| 3 |
Canaan Ix L.p. |
Director |
2,494,381 |
2017-03-28 |
|
| 4 |
Mccarthy Sean A. |
CEO |
1,078,922 |
2026-03-19 |
|
| 5 |
Bvf Partners L P/il |
10 Percent Owner |
358,450 |
2020-12-28 |
|
| 6 |
Belvin Marcia |
SVP, Chief Scientific Officer |
300,760 |
2026-03-19 |
|
| 7 |
Ogden Christopher |
Chief Financial Officer |
296,948 |
2026-03-19 |
|
| 8 |
Chu Yu-waye |
Chief Medical Officer |
189,446 |
2026-03-19 |
|
| 9 |
Rowland Lloyd A |
General Counsel |
120,594 |
2025-03-20 |
|
| 10 |
Kavanaugh William Michael |
CSO, Head Res.&non-clin. Dev. |
120,000 |
2020-02-19 |
|
| 11 |
Landau Jeffrey B |
Chief Business Officer |
110,060 |
2024-03-21 |
|
| 12 |
Humphrey Rachel |
Chief Medical Officer |
90,000 |
2019-01-29 |
|
| 13 |
Ray Debanjan |
Chief Financial Officer |
90,000 |
2019-01-29 |
|
| 14 |
Ladd Cynthia J |
Senior VP and General Counsel |
84,000 |
2017-01-27 |
|
| 15 |
Peterson Amy C. |
EVP, Chief Development Officer |
58,433 |
2023-03-20 |
|
| 16 |
Campoy Carlos |
Chief Financial Officer |
38,224 |
2023-03-20 |
|
| 17 |
Jones Elaine V |
Director |
38,000 |
2025-06-13 |
|
| 18 |
Meyers James R |
Director |
38,000 |
2025-06-13 |
|
| 19 |
Ashworth Alan |
Director |
38,000 |
2025-06-13 |
|
| 20 |
Gilbert Halley E |
Director |
38,000 |
2025-06-13 |
|
Aktuelle Transaktionen (letzte 12 Monate)
| Datum |
Name |
Funktion |
Typ |
Aktien |
Kurs |
Wert |
| 2026-03-17 |
Belvin Marcia |
SVP, Chief Scientific Officer |
Informierter Verkauf |
31,492 |
$6.42 |
$202.27K |
| 2026-03-17 |
Ogden Christopher |
Chief Financial Officer |
Informierter Verkauf |
19,323 |
$6.42 |
$124.11K |
| 2026-03-17 |
Chu Yu-waye |
Chief Medical Officer |
Informierter Verkauf |
21,279 |
$6.42 |
$136.68K |
| 2026-03-17 |
Mccarthy Sean A. |
CEO |
Informierter Verkauf |
118,969 |
$6.42 |
$764.14K |
| 2026-02-02 |
Lester Rachael |
Chief Business Officer |
RSU-Zuteilung |
20,000 |
- |
- |
| 2026-02-02 |
Belvin Marcia |
SVP, Chief Scientific Officer |
RSU-Zuteilung |
250,000 |
$6.09 |
$1.52M |
| 2026-02-02 |
Ogden Christopher |
Chief Financial Officer |
RSU-Zuteilung |
90,000 |
- |
- |
| 2026-02-02 |
Chu Yu-waye |
Chief Medical Officer |
RSU-Zuteilung |
75,000 |
- |
- |
| 2026-02-02 |
Mccarthy Sean A. |
CEO |
RSU-Zuteilung |
980,000 |
$6.09 |
$5.97M |
| 2025-11-06 |
Mccarthy Sean A. |
CEO |
Informierter Verkauf |
101,793 |
$4.54 |
$461.91K |
| 2025-10-20 |
Lester Rachael |
Chief Business Officer |
RSU-Zuteilung |
650,000 |
$3.74 |
$2.43M |
| 2025-10-20 |
Lester Rachael |
Officer |
Unbekannt |
- |
- |
- |
| 2025-09-26 |
Belvin Marcia |
SVP, Chief Scientific Officer |
RSU-Zuteilung |
18,150 |
- |
- |
| 2025-09-26 |
Ogden Christopher |
Chief Financial Officer |
RSU-Zuteilung |
39,150 |
- |
- |
| 2025-09-26 |
Chu Yu-waye |
Chief Medical Officer |
RSU-Zuteilung |
43,750 |
- |
- |
| 2025-09-26 |
Mccarthy Sean A. |
CEO |
RSU-Zuteilung |
285,000 |
- |
- |
| 2025-06-16 |
Belvin Marcia |
SVP, Chief Scientific Officer |
Informierter Verkauf |
13,884 |
$2.69 |
$37.33K |
| 2025-06-13 |
Belvin Marcia |
SVP, Chief Scientific Officer |
Optionsausübung (Verkauf) |
37,500 |
- |
- |
| 2025-06-16 |
Ogden Christopher |
Chief Financial Officer |
Informierter Verkauf |
10,614 |
$2.69 |
$28.54K |
| 2025-06-13 |
Ogden Christopher |
Chief Financial Officer |
Optionsausübung (Verkauf) |
37,500 |
- |
- |
| 2025-06-16 |
Mccarthy Sean A. |
CEO |
Informierter Verkauf |
55,511 |
$2.69 |
$149.26K |
| 2025-06-13 |
Mccarthy Sean A. |
CEO |
Optionsausübung (Verkauf) |
150,000 |
- |
- |
| 2025-06-11 |
Su Zhen |
Director |
RSU-Zuteilung |
38,000 |
$2.82 |
$107.16K |
| 2025-06-11 |
Ashworth Alan |
Director |
RSU-Zuteilung |
38,000 |
$2.82 |
$107.16K |
| 2025-06-11 |
Mohindru Mani |
Director |
RSU-Zuteilung |
38,000 |
$2.82 |
$107.16K |
